Opinion|Videos|November 19, 2024
Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief
Key Takeaways
- Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
- The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) Elinzanetant was studied in the
OASIS 1 and 2 trials , and new data onOASIS 3 were just presented at The Menopause Society’s 2024 Annual Meeting. What was the methodology of these studies? - (SMITH) What are the key findings from the OASIS trials in terms of the reduction in frequency and severity of VMS, and how do these compare with other hormonal and nonhormonal treatments?
- How did elinzanetant impact quality of life for women with severe VMS in the OASIS trials?
- How quickly did patients experience an improvement in symptoms?
- (PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
- (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?
Advertisement
Related to this article
A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
3
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5